selected publications
-
academic article
- GPER-targeted, 99mTc-labeled, nonsteroidal ligands demonstrate selective tumor imaging and in vivo estrogen binding.. Molecular cancer research : MCR. :-. 2014
- Synthesis and characterization of tricarbonyl-Re/Tc(I) chelate probes targeting the G protein-coupled estrogen receptor GPER/GPR30.. PloS one. 7:-. 2012
- Synthesis and characterization of iodinated tetrahydroquinolines targeting the G protein-coupled estrogen receptor GPR30.. Journal of medicinal chemistry. 53:1004-1014. 2010
- Influence of charge on cell permeability and tumor imaging of GPR30-targeted 111in-labeled nonsteroidal imaging agents.. ACS chemical biology. 5:681-690. 2010
- In vivo effects of a GPR30 antagonist.. Nature chemical biology. 5:421-427. 2009
- Enhancement of somatostatin-receptor-targeted (177)Lu-[DOTA(0)-Tyr(3)]-octreotide therapy by gemcitabine pretreatment-mediated receptor uptake, up-regulation and cell cycle modulation.. Nuclear medicine and biology. 35:673-678. 2008
- Preclinical development of a neutral, estrogen receptor-targeted, tridentate 99mTc(I)-estradiol-pyridin-2-yl hydrazine derivative for imaging of breast and endometrial cancers.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 49:978-986. 2008
- Somatostatin-receptor-targeted alpha-emitting 213Bi is therapeutically more effective than beta(-)-emitting 177Lu in human pancreatic adenocarcinoma cells.. Nuclear medicine and biology. 34:185-193. 2007
- Linkage effects on binding affinity and activation of GPR30 and estrogen receptors ERalpha/beta with tridentate pyridin-2-yl hydrazine tricarbonyl-Re/(99m)Tc(I) chelates.. Journal of the American Chemical Society. 128:14476-14477. 2006
- 213Bi-[DOTA0, Tyr3]octreotide peptide receptor radionuclide therapy of pancreatic tumors in a preclinical animal model.. Clinical cancer research : an official journal of the American Association for Cancer Research. 12:897-903. 2006
- A comparison of high- versus low-linear energy transfer somatostatin receptor targeted radionuclide therapy in vitro.. Cancer biotherapy & radiopharmaceuticals. 20:52-57. 2005